Process for obtaining antibodies
The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.
1. A method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; separating the host cell sample from medium in which the host cell was cultured; adding an extraction buffer to the separated host cell sample; detecting the pH of the extraction buffer containing the separated host sample after the extraction buffer is added; and subjecting the sample to a heat treatment step that comprises heating the sample to a temperature ranging from 30° C. to 70° C.
2. The method according to claim 1 , wherein said heat treatment step is performed within the range of 40° C. to 60° C.
3. The method according to claim 1 , wherein the antibody specifically binds to an antigen selected from interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-13, IL-14, IL-16, IL-17, IL17A, IL17F, viral antigens, immunoglobulins, interferon α, interferon β or interferon γ, tumor necrosis factor-α (TNF-α), tumor necrosis factor-β, G-CSF, GM-CSF, PDGF-α, PDGF-β, VLA-4, E-selectin, P selectin, L-selectin, CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD40L, CD45, CDW52, CD69, CD134 (OX40), ICOS, BCMP7, CD137, CD27L, CDCP1, CSF1, CSF1-Receptor, DPCR1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, nectin-like2, NKCC1, PTK7, RAIG1, TCAM1, SC6, BCMP101, BCMP84, BCMP11, DTD, carcinoembryonic antigen (CEA), human milk fat globulin (HMFG1 and 2), MHC Class I antigens, MHC Class II antigens, KDR or VEGF.
4. The method according to claim 1 , wherein the antibody molecule is selected from a VH, VL, VHH, Fab, modified Fab, altered hinge Fab, Fab′, F(ab′) 2 , Fv fragment; a light chain or heavy chain monomer or dimer; a single chain antibody or a dual specificity antibody.
5. The method according to claim 1 , wherein the pH is adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.
6. The method according to claim 3 , wherein said antibody binds to TNF-α.
7. The method according to claim 6 , wherein the antibody is selected from a VH, VL, VHH, Fab, modified Fab, altered hinge Fab, Fab′, F(ab′) 2 , Fv fragment; a light chain or heavy chain monomer or dimer; a single chain antibody or a dual specificity antibody.
8. The method according to claim 7 , wherein said antibody is a Fab′.
9. The method according to claim 1 , wherein said heat treatment step is performed within the range of 40° C. to 65° C.
10. The method according to claim 1 , wherein said heat treatment step is performed within the range of 45° C. to 60° C.
11. The method according to claim 1 , wherein said heat treatment step is performed for a period of between 6 and 16 hours.
12. The method according to claim 1 , wherein said heat treatment step is performed for a period of between 4 and 18 hours.